New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. (Photo: Maria Ponce) https://t.co/h2z5abwqHe https://t.co/7k3mmUwhfT ...

New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. (Photo: Maria Ponce) https://t.co/Ik4ZygR03O https://t.co/tPHZNMna5p ...

New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process. (Photo: Maria Ponce) https://t.co/L8rVPGVJho https://t.co/YEu4NUXCGS ...

19 June 2025 Equity Research Report China Healthcare Equities Demand for innovative drug clinical trials shifting to China amid supportive policies China's clinical efficiency leap: Catching up with the world with strengthened competitiveness. The National Medical Product Administration (NMPA) published a circular in June, proposing to reduce the review and approval time of clinical trial applications for all innovative drugs to 30 days from the previous 60 days, following the pilot programme in July 2024. ...

Anti-TL1A Phase 1 Results and Phase 2 Development Updates June 2025 Disclosures The information contained in this presentation has been prepared by Spyre Therapeutics, Inc. and its affiliates ("Spyre" or the "Company") and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data as well as t ...

Thakral succeeds Interim CEO, Peter M. Neupert, who will remain chairman of the board DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that Fortrea’s Board of Directors (the “Board”) named Anshul Thakral as Fortrea’s CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company’s Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will r ...

When I covered Black Diamond Therapeutics (NASDAQ: BDTX ) earlier this year , I did not find their decline justified by the facts, particularly in light of upcoming trial readouts in an areaI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space ...

ICON Public Company (ICLR) FY Conference June 04, 2025 11:40 AM ET Speaker0 Alright. Good morning, everyone, and thanks for joining us today for the management presentation. My name is Max Mach, and I'm the research analyst here at William Blair who covers Icon. We're pleased to be joined this morning by CEO, doctor Steve Cutler, and Kate Haven, vice president, investor relations. Before we get into the presentation, I have to mention two things. First, the breakout session will be held in Adler on the seco ...

UroGen Pharma (URGN) FY Conference May 28, 2025 09:00 AM ET Speaker0 Morning, everyone. I'm Tara Bancroft. I'm one of the senior biotech analysts at TD Cowen. I wanna thank you very much for joining our sixth annual oncology innovation summit. And so to start off the day, in the first session, we have a q and a with UroGen, and it's my pleasure to introduce Liz Barrett, the president and CEO, and Mark Schoenberg, the CMO. So it's a privilege to have you both here. Thank you. Thank you for being here with us ...

CHAMBERS GLOBAL PRACTICE GUIDES Life Sciences 2025 Definitive global law guides offering comparative analysis from top-ranked lawyers China: Law & Practice Alan Zhou, Coco Fan, Kelly Cao and Stephanie Wang Global Law Office CHINA Law and Practice Contributed by: Alan Zhou, Coco Fan, Kelly Cao and Stephanie Wang Global Law Office Contents 1. Life Sciences Regulatory Framework p.6 2. Clinical Trials p.7 3. Marketing Authorisations for Pharmaceuticals or Medical Devices p.10 4. Regulatory Reliance and Fast Tra ...